Table 1.
Patient demographic summary
| No. | Age | KPS | Histologic Diagnosis | Therapy Prior to TP-38 | TP-38 (ng/ml) | Therapy after TP-38 |
|---|---|---|---|---|---|---|
| Residual tumor | ||||||
| 2 | 59 | 80 | GBM | OR, EBRT, carmustine, cisplatin, etoposide, carmustine wafers/temozolomide, irinotecan, cyclophosphamide, tamoxifen | 25 | None |
| 3 | 40 | 80 | GBM | OR, EBRT, carmustine/mercaptopurine × 1, EBRT, lomustine × 6, temozolomide × 6 | 25 | None |
| 4 | 55 | 60 | GBM | OR × 2, 131I-monoclonal antibody, EBRT, temozolomide × 2, lomustine × 4, etoposide, irinotecan/temozolomide | 25 | Thalidomide |
| 5 | 55 | 60 | GBM | OR, EBRT, procarbazine/lomustine/vincristine × 6, temozolomide/tamoxifen × 4, OR | 50 | None |
| 6 | 51 | 90 | GBM | OR × 2 EBRT, lomustine × 6 | 50 | Temozolomide |
| 8 | 55 | 90 | GBM | OR, EBRT, lomustine × 2, radiosurgery, temozolomide × 5, OR | 50 | None |
| 9 | 58 | 90 | GSC | OR, OR, EBRT, carmustine/irinotecan × 1, temozolomide × 4, tamoxifen × 4 | 50 | Etoposide |
| 10 | 45 | 90 | GBM | OR, EBRT, OR, 131I-monoclonal antibody, EBRT, temozolomide × 4, lomustine × 4, etoposide × 2, temozolomide × 1, lomustine × 4 | 50 | None |
| 13 | 52 | 90 | GBM | OR, EBRT, lomustine × 2, temozolomide × 2, irofulven × 3 | 50 | Irinotecan |
| 15 | 62 | 70 | GBM | OR, 125I brachytherapy, EBRT, Cu2+ chelation, temozolomide × 9, irinotecan × 8 | 100 | None |
| 16 | 49 | 90 | GBM | OR, EBRT, temozolomide | 100 | None |
| 17 | 50 | 90 | AO | OR, EBRT, procarbazine/lomustine/vincristine × 6, OR | 100 | Temozolomide/ irinotecan × 5 |
| 18 | 48 | 90 | GBM | OR, EBRT | 100 | None |
| 19 | 31 | 90 | GBM | OR, EBRT | 100 | Irinotecan |
| 20 | 21 | 90 | GBM | OR × 2, EBRT | 100 | None |
| No residual tumor | ||||||
| 1 | 59 | 90 | GBM | OR, EBRT, lomustine × 2, etoposide/tamoxifen × 2, irinotecan × 2, lomustine × 1, temozolomide × 3, thalidomide, radiosurgery, topotecan | 25 | None |
| 7 | 23 | 90 | Metastatic spindle cell | None for brain metastasis | 25 | Temozolomide/ imatinib mesylate |
| 11 | 56 | 90 | GBM | OR, EBRT, carmustine × 2, OR | 25 | Temozolomide/ O6-benzylguanine |
| 12 | 55 | 90 | GBM | OR, EBRT, lomustine × 2, temozolomide × 2, OR | 50 | None |
| 14 | 68 | 100 | GBM | OR, radiosurgery, EBRT, temozolomide × 1 | 50 | OSI-774 |
Abbreviations: GBM, glioblastoma multiforme; OR, operative resection; EBRT, external beam radiation therapy; GSC, gliosarcoma; AO, anaplastic oligodendroglioma.